Kantos (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, suppressing the production of inflammatory mediators and reducing swelling and mucus formation. This anti‑inflammatory action helps to prevent asthma and COPD symptoms such as wheezing, coughing, and shortness of breath.

The dose of Kantos is individualized by the prescribing clinician based on the severity of the patient’s asthma or COPD, age, and response to therapy. The prescriber determines the number of inhalations per day and the total daily dose, which should be followed exactly as instructed.

Safety data for Kantos in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To request Kantos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Kantos combines an inhaled corticosteroid (beclometasone) with a long‑acting β2‑agonist (formoterol) in a single inhaler, offering both anti‑inflammatory and bronchodilator effects. Compared with single‑component inhalers, this combination can simplify treatment regimens and improve adherence, while providing rapid onset bronchodilation similar to other LABA‑containing products.

Kantos should be stored at ambient temperature, below 25 °C. Keep the inhaler in its original packaging, protect it from moisture and direct sunlight, and ensure the mouthpiece remains clean to maintain dose accuracy and product stability.

Kantos is delivered by inhalation using a metered‑dose inhaler. The patient inhales a prescribed number of puffs, typically after exhaling fully, and holds their breath for a few seconds to allow the medication to reach the lower airways. Using a spacer can improve drug deposition and reduce oral side effects.

Serious risks include paradoxical bronchospasm, which can worsen breathing shortly after inhalation, severe allergic reactions such as anaphylaxis, and cardiac arrhythmias, especially in patients with underlying heart disease. Patients should seek immediate medical attention if they experience sudden breathlessness, swelling, rash, or irregular heartbeats.

Kantos is contraindicated in patients with a known hypersensitivity to beclometasone, formoterol, or any component of the inhaler. It should also be avoided in individuals who have experienced a severe paradoxical bronchospasm with previous use of inhaled β2‑agonists. Clinicians must assess each patient’s medical history before prescribing.